Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.026
Neutral
RSI(14)
56.841
Neutral
STOCH(KDJ)(9,3,3)
75.849
Neutral
ATR(14)
1.769
High Vlolatility
CCI(14)
57.787
Neutral
Williams %R
29.012
Buy
TRIX(12,20)
0.615
Sell
StochRSI(14)
0.000
Sell
Upstream Bio Inc
UPB29.480USD
-0.790-2.61%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Upstream Bio Inc
Currency: USD Updated: 2025-12-26Key Insights
Upstream Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 42/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 48.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Upstream Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
48.000
Target Price
+65.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Upstream Bio Inc Highlights
StrengthsRisks
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 95.54% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.37M.
Undervalued
The company’s latest PE is -12.80, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.98M shares, increasing 1.65% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 51.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Upstream Bio Inc is 6.40, ranking 269/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 683.00K, representing a year-over-year increase of 12.52%, while its net profit experienced a year-over-year increase of 60.45%.
Score
Financials
8.22
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.18
Operational Efficiency
2.83
Growth Potential
6.71
Shareholder Returns
7.07
Upstream Bio Inc's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Upstream Bio Inc is 6.75, ranking 236/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.80, which is -64.26% below the recent high of -4.58 and -57.82% above the recent low of -20.21.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 42/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Upstream Bio Inc is 8.33, ranking 139/404 in the Biotechnology & Medical Research industry. The average price target for Upstream Bio Inc is 43.00, with a high of 75.00 and a low of 35.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
48.000
Target Price
+65.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Upstream Bio Inc
UPB
7
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Upstream Bio Inc is 9.23, ranking 39/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 32.04 and the support level at 25.76, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
29.748
Sell
MA10
29.059
Buy
MA20
28.456
Buy
MA50
25.925
Buy
MA100
21.932
Buy
MA200
15.903
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Upstream Bio Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 94.34%, representing a quarter-over-quarter decrease of 9.72%. The largest institutional shareholder is The Vanguard, holding a total of 2.44M shares, representing 4.52% of shares outstanding, with 167.31% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
OrbiMed Advisors, LLC
Access Industries, Inc.
Decheng Capital LLC
Norges Bank Investment Management (NBIM)
Enavate Sciences GP, LLC
Bain Capital Life Sciences Investors, LLC
HBM Partners AG
TCG Crossover Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Upstream Bio Inc is 4.55, ranking 86/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+49.42%
240-Day Volatility
+92.83%
Return
Best Daily Return
60 days
+10.67%
120 days
+18.27%
5 years
--
Worst Daily Return
60 days
-13.70%
120 days
-13.70%
5 years
--
Sharpe Ratio
60 days
+3.09
120 days
+3.14
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+49.42%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+3.20
3 years
--
5 years
--
Skewness
240 days
+0.20
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+92.83%
5 years
--
Standardised True Range
240 days
+3.88%
5 years
--
Downside Risk-Adjusted Return
120 days
+633.31%
240 days
+633.31%
Maximum Daily Upside Volatility
60 days
+52.75%
Maximum Daily Downside Volatility
60 days
+41.76%
Liquidity
Average Turnover Rate
60 days
+0.90%
120 days
+0.75%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Upstream Bio Inc
UPB
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Upstream Bio Inc?
The TradingKey Stock Score provides a comprehensive assessment of Upstream Bio Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Upstream Bio Inc’s performance and outlook.
How do we generate the financial health score of Upstream Bio Inc?
To generate the financial health score of Upstream Bio Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Upstream Bio Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Upstream Bio Inc.
How do we generate the company valuation score of Upstream Bio Inc?
To generate the company valuation score of Upstream Bio Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Upstream Bio Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Upstream Bio Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Upstream Bio Inc.
How do we generate the earnings forecast score of Upstream Bio Inc?
To calculate the earnings forecast score of Upstream Bio Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Upstream Bio Inc’s future.
How do we generate the price momentum score of Upstream Bio Inc?
When generating the price momentum score for Upstream Bio Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Upstream Bio Inc’s prices. A higher score indicates a more stable short-term price trend for Upstream Bio Inc.
How do we generate the institutional confidence score of Upstream Bio Inc?
To generate the institutional confidence score of Upstream Bio Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Upstream Bio Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Upstream Bio Inc.
How do we generate the risk management score of Upstream Bio Inc?
To assess the risk management score of Upstream Bio Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Upstream Bio Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Upstream Bio Inc.
